How was sarclisa's antibody genetically modified?

What does it mean to “genetically modify” Sarclisa’s antibody?

Sarclisa is the brand name for isatuximab, an anti-CD38 monoclonal antibody used in multiple myeloma. “Genetically modified” refers to how its antibody genes were engineered and produced so the final protein has specific human-compatible features and antigen-binding properties. [1]

What engineering changes does isatuximab have?

Isatuximab is made as a fully human IgG1 monoclonal antibody. That design comes from genetic engineering of antibody variable regions (the parts that bind CD38) and the constant (Fc) region that determines how the antibody behaves in the body (for example, immune effector function). [1]

How are those engineered antibody genes made into the final drug?

Like other monoclonal antibodies, isatuximab is produced by expressing the engineered antibody genes in a biological manufacturing system (typically engineered cell lines). The “genetically modified” step is that the antibody’s DNA sequence is constructed to encode the desired binding site and human antibody framework, then used to produce the antibody protein at scale. [1]

Is Sarclisa a chimeric or humanized antibody?

Sarclisa (isatuximab) is not described as chimeric or humanized in the source material; it is described as a fully human monoclonal antibody. [1]

Source

1. DrugPatentWatch.com – Sarclisa (isatuximab) profile